Related Experiment Video
Updated: Aug 8, 2026

05:10
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
Renovations Needed: the FDA's Floor/Ceiling Framework, Preemption, and the Opioid Epidemic
Summary
The FDA's regulatory system for drugs is imbalanced, failing to hold pharmaceutical companies accountable for the opioid crisis. This leads to inadequate compensation for victims and allows companies to avoid public health costs.
Area of Science:
- Pharmaceutical regulation
- Public health policy
- Legal studies
Background:
- The U.S. Food and Drug Administration (FDA) employs a regulatory framework for pharmaceuticals characterized by a "floor/ceiling" model.
- Administrative rules establish a minimum safety "floor," while state tort liability provides a "ceiling" for maximum protection.
- This system prioritizes pre-market review but relies heavily on post-market state common law to regulate pharmaceutical products.
Purpose of the Study:
- To analyze the imbalance in the FDA's regulatory framework, particularly concerning the opioid crisis.
- To examine how the preemption of state tort law by federal standards exacerbates this imbalance.
- To argue that the current FDA framework misallocates the costs of the opioid epidemic and inadequately compensates injured parties.
Main Methods:
- Review of the FDA's regulatory framework for opioid medications.
- Analysis of the compensatory problem arising from the framework, focusing on the internalization of negative externalities by pharmaceutical manufacturers.
- Proposal of a victims' compensation fund as an alternative to state tort liability.
Main Results:
- The increasing preemption of state tort law by federal administrative standards has created an imbalance in the FDA's regulatory framework.
- This imbalance allows the pharmaceutical industry to avoid bearing the public health costs associated with their opioid products.
- The existing framework fails to adequately compensate individuals harmed by prescription opioid medications.
Conclusions:
- The FDA's current administrative design inadequately addresses the financial and public health consequences of the opioid epidemic.
- Pharmaceutical manufacturers are not fully internalizing the societal costs of their opioid products due to regulatory loopholes.
- A dedicated victims' compensation fund is proposed as a viable mechanism to replace the protective functions of state tort liability and ensure victim compensation.
Related Concept Videos
Drug Regulation
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
Prescription, Nonprescription and Orphan Drugs
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
Drug Control Governance: Regulatory Bodies and Their Impact
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with a...
Drug Administration and Therapy Phases: Overview
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
FDA Approved Drugs: Changes to Approved Drugs
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...

